Short-Term Anatomic Effect of Ranibizumab for Polypoidal Choroidal Vasculopathy

Reche-Frutos, J; Calvo-González, C; Donate-López, J.; García‐Feijoó, Julián; Leila, Mahmoud; García–Sánchez, J.

doi:10.1177/112067210801800427

Cited by 35 publications

(30 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other reports related to intravitreal ranibizumab monotherapy for the treatment of PCV, 0–33% of polypoidal lesions showed regression [23,24,28]. Considering these reports and our study, we have come to the conclusion that combined treatment would be better than ranibizumab monotherapy for the regression of polyps, although some reported that 70% of polyps regressed on ICGA after intravitreal ranibizumab monotherapy [22]. …”

Section: Discussionmentioning

confidence: 57%

“…The reports of greater expression of VEGF in histopathology and increased VEGF in the aqueous humor have suggested the association of PCV and VEGF [16,17]. Some of the reports present that the anti-VEGF treatment might be a potential treatment to improve PCV [19,20,21,22,23,24,27]. Conversely, in terms of the polyp regression rate, anti-VEGF monotherapy could be inferior to PDT monotherapy or intravitreal anti-VEGF treatment combined with PDT [19,27].…”

Section: Discussionmentioning

confidence: 99%

“…Gomi et al [18] recommended that further study of ranibizumab, which has a smaller molecular mass and high affinity for VEGF, should be done in treating PCV. The short-term outcome of ranibizumab was prospective in PCV, though no long-term studies have been conducted [22,23,24]. Lai et al [19] recommended the usefulness of the combination of PDT and intravitreal bevacizumab.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

One-Year Results of Intravitreal Ranibizumab with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

2011

View full text Add to dashboard Cite

Purpose: To evaluate the safety and efficacy of intravitreal ranibizumab with or without photodynamic therapy (PDT) in the treatment of polypoidal choroidal vasculopathy (PCV) in Korean patients. Methods: A retrospective chart review of 22 patients (24 eyes) with PCV was conducted. Nine eyes were treated with intravitreal ranibizumab combined with a single session of PDT (group 1), and 15 eyes were treated only with ranibizumab (group 2). Such clinical evaluations as best-corrected Snellen visual acuity, central retinal thickness (CRT) by optical coherence tomography (OCT), fluorescein angiography (FA) and indocyanine green angiography (ICGA) were done at baseline, 1, 3, 6, 9 and 12 months after the first injections. Ranibizumab was reinjected on an as-needed basis guided by OCT, FA and ICGA, or at the doctor’s discretion. Results: The mean follow-up duration was 22.5 months (range 12–37). The mean best-corrected visual acuity (logMAR) improved, and the mean CRT decreased throughout 12 months in both groups; no statistically significant difference between the groups was found (p = 0.327, p = 0.073, respectively). The number of ranibizumab injections was not significantly different either (p = 0.555). Conclusions: Intravitreal ranibizumab with or without PDT for PCV in Korean patients resulted in visual and anatomical improvement over the 1-year follow-up period.

show abstract

Section: Discussionmentioning

confidence: 57%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

One-Year Results of Intravitreal Ranibizumab with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

2011

View full text Add to dashboard Cite

show abstract

“…As mentioned above, Terasaki et al 19 and Matsuoko et al 20 reported increased VEGF staining and expression on the vascular endothelium of PCV specimens. Initial clinical experience suggests that PCV respond well to anti-VEGF therapy, with rapid resolution of retinal thickening and exudate accumulation, 42,43 and increase in vision. 44 However, both Gomi et al 45 and Lai et al 46 reported that although anti-VEGF monotherapy reduces macular thickness and improved vision in patients with PCV, the majority of the polyps remained.…”

Section: Anti-vascular Endothelial Growth Factor Therapy For Pcvmentioning

confidence: 99%

Polypoidal choroidal vasculopathy: an angiographic discussion

Lim

Laude

Tan

2010

Eye

View full text Add to dashboard Cite

The understanding of polypoidal choroidal vasculopathy has evolved rapidly in the past three decades. The hallmark of the disease is the presence of typical hyperfluorescent nodules in the early phase of indocyanine green angiography. Although the classical clinical presentation is recurrent serosanguinous detachment of the retinal pigment epithelium, it may present with clinical features indistinguishable from exudative age-related macular degeneration secondary to choroidal neovascularization. Some cases may present initially with submacular haemorrhage, but later with features of exudative age-related macular degeneration. Studying the associated network of vessels using confocal scanning laser ophthalmoscopy indocyanine green dynamic angiography revealed in many cases feeder vessels, branching pattern, and leakage similar to choroidal neovascularization. Owing to the overlap of clinical and angiographic features, it may be considered as a vascular subtype of exudative age-related macular degeneration. However, having seemingly better natural history, better response to photodynamic therapy, and incomplete response to antivascular endothelial growth factor therapy suggests that it should be studied as a separate entity from choroidal neovascularization. Combining angio-occlusion of the polyps using photodynamic therapy and antipermeability effect of anti-vascular endothelial growth factor therapy on the branching vascular network may provide a synergistic effect. We await the result of EVEREST trial, a multi-centre randomized controlled trial comparing photodynamic therapy, with or without ranibizumab, with ranibizumab monotherapy.

show abstract

“…Results with this smaller molecular weight compound are promising, showing regression of polypoidal changes (16,17) . A combination of PDT therapy and ranibizumab could provide a good alternative, by reducing the number of injections needed relative to that used in other anti-VEGF monotherapy.There are also reports of phototrombosis of neovessels, mediated by indocyanine green (18) .…”

Section: Introductionmentioning

confidence: 98%

Polypoidal choroidal vasculopathy causing cystoid macular edema and the response to Ranibizumb intravitreal treatment

Amaro¹,

Roller²,

Motta³

et al. 2011

Rev. bras.oftalmol.

View full text Add to dashboard Cite

show abstract

Short-Term Anatomic Effect of Ranibizumab for Polypoidal Choroidal Vasculopathy

Abstract: Monthly intravitreal injection of ranibizumab for 3 months has a short-term beneficial anatomic effect.

Cited by 35 publications

References 6 publications

One-Year Results of Intravitreal Ranibizumab with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

One-Year Results of Intravitreal Ranibizumab with or without Photodynamic Therapy for Polypoidal Choroidal Vasculopathy

Polypoidal choroidal vasculopathy: an angiographic discussion

Polypoidal choroidal vasculopathy causing cystoid macular edema and the response to Ranibizumb intravitreal treatment

Contact Info

Product

Resources

About